Sanofi
13F Reported Value
ⓘ$336.0M
Holdings
9
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Sanofi disclosed 9 positions worth $336.0M in its Form 13F-HR for Q1 2026, led by $MGTX (MeiraGTx Holdings plc) at 31.4% of the equity portfolio, followed by $INBX and $NVAX. During the quarter the fund opened 1 new position and exited 0 — including a new stake in $AGMB. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Sanofi’s Form 13F-HR filing with the SEC under CIK 1121404.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$105.6M12,197,737 sh - 3.1#2,860
Quality
$77.8M1,157,926 sh - 65.5#572
Quality
$56.0M6,880,481 sh - 29.4
Quality
$30.4M821,917 sh - —
Quality
$29.2M2,783,096 sh - —
Quality
$18.5M912,041 sh - —
Quality
$14.3M2,708,559 sh - —
Quality
$2.5M814,980 sh - 23.1
Quality
$1.6M244,083 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 MeiraGTx Holdings plc$MGTX | — | $105.6M | 12,197,737 |
 Inhibrx Biosciences, Inc.$INBX | 3.1#2,860 | $77.8M | 1,157,926 |
 NOVAVAX INC$NVAX | 65.5#572 | $56.0M | 6,880,481 |
 ANAPTYSBIO, INC$ANAB | 29.4 | $30.4M | 821,917 |
 Agomab Therapeutics NV$AGMB | — | $29.2M | 2,783,096 |
 MapLight Therapeutics, Inc.$MPLT | — | $18.5M | 912,041 |
 Immuneering Corp$IMRX | — | $14.3M | 2,708,559 |
 Eledon Pharmaceuticals, Inc.$ELDN | — | $2.5M | 814,980 |
 Q32 Bio Inc.$QTTB | 23.1 | $1.6M | 244,083 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Sanofi's 9 positions.
Showing top 9 of 9 holdings.
Sector Allocation
Healthcare
$336.0M
Full Holdings — Sanofi (Q1 2026)
All 9 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $MGTX | MeiraGTx Holdings plc | $105.6M | 31.4% | +0% | — |
| 2 | $INBX | Inhibrx Biosciences, Inc. | $77.8M | 23.2% | +0% | 3.1 |
| 3 | $NVAX | NOVAVAX INC | $56.0M | 16.7% | +0% | 65.5 |
| 4 | $ANAB | ANAPTYSBIO, INC | $30.4M | 9.0% | +0% | 29.4 |
| 5 | $AGMB | Agomab Therapeutics NV | $29.2M | 8.7% | NEW | — |
| 6 | $MPLT | MapLight Therapeutics, Inc. | $18.5M | 5.5% | +0% | — |
| 7 | $IMRX | Immuneering Corp | $14.3M | 4.3% | +0% | — |
| 8 | $ELDN | Eledon Pharmaceuticals, Inc. | $2.5M | 0.8% | +0% | — |
| 9 | $QTTB | Q32 Bio Inc. | $1.6M | 0.5% | +0% | 23.1 |
New Positions (1)
$AGMB Agomab Therapeutics NV$29.2MBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Sanofi including:
Track Sanofi's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Sanofi and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Sanofi
13F Pro is an AI hedge fund tracker and stock research platform. For Sanofi (SEC CIK: 1121404), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Sanofi's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.